Cox-2 inhibition potentiates mouse bone marrow stem cell engraftment and differentiation-mediated wound repair

Geesala, Ramasatyaveni; Dhoke, Neha R.; Das, Amitava

doi:10.1016/j.jcyt.2017.03.072

Cited by 22 publications

(17 citation statements)

References 53 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is worth noting that mice deficient of IL-17A had lower IL-1β and IL-6 expression. Consistently, experimental studies by others had shown that IL-17A was able to promote the production of IL-1β, IL-6, TNF-α by macrophages, 44 and in collagen-induced arthritis mice, IL-17A increased the synovial expression of IL-1β and IL-6. 45 Our findings here suggest a regulatory role of IL-17A in production of proinflammatory cytokines, which are probably involved in CS-induced osteoclastogenesis in this model.…”

Section: Discussionsupporting

confidence: 81%

<p>Interleukin-17A Deficiency Attenuated Emphysema and Bone Loss in Mice Exposed to Cigarette Smoke</p>

Xiong¹,

Tian²,

Zhou³

et al. 2020

COPD

View full text Add to dashboard Cite

Background and Purpose: Chronic obstructive pulmonary disease (COPD) is a common chronic inflammatory disease, which is associated with various comorbidities including osteoporosis. Interleukin(IL)-17 has been reported to play important roles in the pathogenesis of COPD and also associated with bone destruction in inflammatory diseases. However, the role of IL-17A in COPD-related osteoporosis is yet unknown. The purpose of our study was to investigate the potential contribution of IL-17A in COPD-related bone loss. Materials and Methods: We examined the bone mass and bone microarchitecture in wildtype and IL-17A -/mice exposed to long-term cigarette smoke (CS). Osteoclast activities and the expression of receptor activator of nuclear factor-κB ligand (RANKL) in bone tissues were assessed, and the blood levels of inflammatory cytokines were measured. Results: Less bone loss as well as attenuated emphysema were shown in IL-17A -/mice compared with wild-type mice. CS-exposed IL-17A -/mice had decreased TRAP+ osteoclast numbers and lower RANKL expression compared with CS-exposed wild-type mice. Inflammatory cytokines including IL-6 and IL-1β in circulation were decreased in IL-17A -/mice exposed to CS compared with wild-type mice. Conclusion: This study indicates that IL-17A is involved in CS-induced bone loss and may be a common link between COPD and osteoporosis.

show abstract

Section: Discussionsupporting

confidence: 81%

<p>Interleukin-17A Deficiency Attenuated Emphysema and Bone Loss in Mice Exposed to Cigarette Smoke</p>

Xiong¹,

Tian²,

Zhou³

et al. 2020

COPD

View full text Add to dashboard Cite

show abstract

“…This leads to an overabundance of compounds designed to break down the damaged extracellular membrane of the wound site, which prevents fibroblast accumulation within the wound site and ultimately prevents progression to the proliferative phase [23]. There are indications that locally acting anti-inflammatory drugs may help chronic wounds to progress past the inflammatory phase by relieving this excessive inflammation [24][25][26]. Therefore, in addition to being a convenient model analgesic compound, the anti-inflammatory properties of diclofenac sodium could be well suited to expediting the healing process of chronic wounds.…”

Section: Introductionmentioning

confidence: 99%

Rheological and Drug Delivery Characteristics of Poloxamer-Based Diclofenac Sodium Formulations for Chronic Wound Site Analgesia

2020

View full text Add to dashboard Cite

Chronic wounds are a significant and growing health problem, and clinical treatment is often a painful experience. A topical dosage form would be optimal to treat this pain. Poloxamer 407, a thermosensitive polymer that is a liquid at low temperatures but gels at higher temperatures, is well suited to administer topical analgesics to chronic wound sites. The goal of this study was to evaluate the gelation and drug delivery properties of poloxamer 407 gels containing diclofenac sodium for potential use in chronic wound analgesic delivery. The gelation properties of poloxamer formulations were evaluated rheologically. Drug delivery properties of poloxamers loaded with diclofenac sodium were evaluated using snakeskin dialysis membranes, intact porcine ear skin, and porcine ear skin impaired via tape stripping. A commercial gel product and a solution of diclofenac sodium in water were used as control formulations. Poloxamer concentration and gelation temperature varied inversely, and the addition of higher concentrations of diclofenac sodium correlated to significant increases in poloxamer gelation temperature. Poloxamer solutions were effective in limiting the permeation of diclofenac sodium through membranes with impaired barrier properties, and delivery of diclofenac sodium from poloxamer 407 did not vary significantly from delivery observed from the commercial gel product. The amount of drug delivered in 24 h did not change significantly with changes in poloxamer 407 concentration. The results of this study indicate that poloxamer 407 may be a useful formulation component for administration of an analgesic product to a chronic wound site.

show abstract

“…(2017) transplanted stem cells with or without the oral cyclooxygenase (COX)-2 inhibitor, celecoxib. In this study, they observed increased engraftment and differentiation of stem cells leading to enhanced wound tissue repair when the cells were transplanted with celecoxib 34 . PG, belongs to the group of thiazolidinediones (TZDs) which are synthetic high-affinity ligands of PPARγ; it is a potent anti-inflammatory drug known to reduce the production of inflammatory cytokines after brain injury 35–37 , including IL1-β and IL6 15–17 , tumor necrosis factor α (TNFα), inducible nitric oxide synthase (iNOS), matrix metalloproteinase (MMP)-9 and COX-2 in macrophage, glial cells, and neurons 38 .…”

Section: Discussionmentioning

confidence: 74%

Pioglitazone treatment prior to transplantation improves the efficacy of human mesenchymal stem cells after traumatic brain injury in rats

Das

Mayilsamy

Tang

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Traumatic brain injury is a leading cause of death and disability around the world. So far, drugs are not available to repair brain damage. Human mesenchymal stem cell (hMSC) transplantation therapy is a promising approach, although the inflammatory microenvironment of the injured brain affects the efficacy of transplanted hMSCs. We hypothesize that reducing the inflammation in the cerebral microenvironment by reducing pro-inflammatory chemokines prior to hMSC administration will improve the efficacy of hMSC therapy. In a rat model of lateral fluid percussion injury, combined pioglitazone (PG) and hMSC (combination) treatment showed less anxiety-like behavior and improved sensorimotor responses to a noxious cold stimulus. Significant reduction in brain lesion volume, neurodegeneration, microgliosis and astrogliosis were observed after combination treatment. TBI induced expression of inflammatory chemokine CCL20 and IL1-β were significantly decreased in the combination treatment group. Combination treatment significantly increased brain-derived neurotrophic factor (BDNF) level and subventricular zone (SVZ) neurogenesis. Taken together, reducing proinflammatory cytokine expression in the cerebral tissues after TBI by PG administration and prior to hMSC therapy improves the outcome of the therapy in which BDNF could have a role.

show abstract

Cox-2 inhibition potentiates mouse bone marrow stem cell engraftment and differentiation-mediated wound repair

Cited by 22 publications

References 53 publications

<p>Interleukin-17A Deficiency Attenuated Emphysema and Bone Loss in Mice Exposed to Cigarette Smoke</p>

<p>Interleukin-17A Deficiency Attenuated Emphysema and Bone Loss in Mice Exposed to Cigarette Smoke</p>

Rheological and Drug Delivery Characteristics of Poloxamer-Based Diclofenac Sodium Formulations for Chronic Wound Site Analgesia

Pioglitazone treatment prior to transplantation improves the efficacy of human mesenchymal stem cells after traumatic brain injury in rats

Contact Info

Product

Resources

About